IP Library Granted Patent US 8,580,503
Granted Patent B2
US 8,580,503 · App. 12/864,424 · Granted Nov 12, 2013

Methods and compositions for diagnosing complications of pregnancy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,503
App. No.
12/864,424
Granted
Nov 12, 2013
Kind
B2
Abstract

The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.

Claims (8)

1. A method for determining whether a pregnant female subject is at risk of developing preeclampsia, and a treatment strategy for said female subject based on said determination comprising: obtaining a biological test sample from said female subject and a control biological sample from a pregnant woman of same gestational age with no clinical or laboratory evidence of hypertensive disorder of pregnancy; extracting microRNA molecules from the test biological sample and the control biological sample; determining the expression of the nucleic acid sequence SEQ ID NO: 17 in the test biological sample and the control biological sample; determining whether said pregnant female subject is at risk of developing preeclampsia based on increased expression of SEQ ID NO: 17 in the test biological sample relative to the control biological sample; and determining a treatment strategy for said pregnant female based on the increased expression of SEQ ID NO: 17 in the test biological sample relative to the control biological sample.

2. The method of claim 1 , wherein said biological sample is selected from the group consisting of bodily fluid and a tissue sample.

3. The method of claim 2 , wherein said tissue is a fresh, frozen, fixed, wax-embedded or formalin fixed paraffin-embedded (FFPE) tissue.

4. The method of claim 3 , wherein said tissue sample is placenta sample or uterine myometrium sample.

5. The method of claim 2 , wherein said bodily fluid sample is serum sample.

6. The method of claim 1 , wherein the expression is determined by a method selected from the group consisting of nucleic acid hybridization and nucleic acid amplification.

7. The method of claim 6 , wherein the nucleic acid hybridization is performed using a solid-phase nucleic acid biochip array or in situ hybridization.

8. The method of claim 6 , wherein the nucleic acid amplification method is real-time PCR.

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2010
From: GOREN, YARON; GILAD, SHLOMIT; HOD, MOSHE; YOGEV, YARIV
To: ROSETTA GENOMICS LTD.; MOR RESEARCH APPLICATIONS
Reel/Frame 024734/0500 →